Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, Sept. 24, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ ABC Test (Influenza A/Influenza B/COVID-19) is anticipated to...

Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19

The company's stock had a huge week after announcing that Arches Research has signed a deal to use its coronavirus test kit.

Is Co-Diagnostics Stock a Buy?

SALT LAKE CITY, Sept. 11, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Announces Details to Access Presentation at H.C.

Becton, Dickinson and Co.

Fluidigm

Even top diagnostic test producers got hit hard in late August.

Why Shares of These 3 Coronavirus-Test Makers Saw Big Moves in August

Co-Diagnostics, Inc. (NASDAQ: CODX) shares shot up on Tuesday after the company announced that it has entered into an agreement with Arches Research to expand Arches’ COVID-19 testing services using Co-Diagnostics’ test kit.

Co-Diagnostics Roars Back With New COVID-19 Test Deal

Good news could be fueling a short squeeze.

Why Co-Diagnostics Stock Is Skyrocketing Today

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that its subsidiary, Arches Research, Inc.

PolarityTE Announces Strategic Partnership with Co-Diagnostics to Expand COVID-19 Testing Platform

The most likely culprit: continued concerns about a competitor's new product.

Why Co-Diagnostics Shares Sank Today While the Stock Market Jumped

SALT LAKE CITY, Sept. 1, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Issues Operational Update

Ichor Hlds

Novavax

CarParts.com, Inc.

Textainer Group Holdings Limited

Tata Motors

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

Top Small Cap Stocks for September 2020

GenMark Diagnostics

QuidelOrtho Corp

Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.

COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test

Luminex

OPKO Health

Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today

Altimmune

iBio

Vaxart

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.

These 5 Healthcare Stocks Are the Biggest Winners in 2020

SALT LAKE CITY, Aug. 25, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C.

SALT LAKE CITY, Aug. 20, 2020 /PRNewswire/ -- Co-Diagnostics, Inc.

Co-Diagnostics, Inc. Receives Enhanced U.S.

Co-Diagnostics Inc. (CODX) CEO Dwight H Egan on Q2 2020 Results - Earnings Call Transcript

Los Angeles, California--(Newsfile Corp. - August 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc.

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, Aug. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Co-Diagnostics, Inc.

CODX FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Reminds Co-Diagnostics, Inc. Investors of the Important August 17 Deadline in Securities Class Action - CODX

New York, New York--(Newsfile Corp. - August 17, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Co-Diagnostics, Inc.

CODX LOOMING DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Co-Diagnostics, Inc. and Lead Plaintiff Deadline: August 17, 2020

New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Co-Diagnostics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Co-Diagnostics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2020 - CODX

Los Angeles, California--(Newsfile Corp. - August 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Co-Diagnostics, Inc.

DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Co-Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 14, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Co-Diagnostics, Inc.

CODX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2020 in the Class Action Filed on Behalf of Co-Diagnostics, Inc. Limited Shareholders

LOS ANGELES--(BUSINESS WIRE)---- $CODX #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Co-Diagnostics, Inc.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Co-Diagnostics, Inc.

A sharp increase in revenue and a flip into profitability were not enough to satisfy investors.

Co-Diagnostics Plummets 16% After Hours on Q2 Misses

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.51% and -10.96%, respectively, for the quarter ended June 2020.

News for Co-Diagnostics Stock (CODX)